Neutrophil cell membranes and inflammatory proteins

Neutrophil cell membranes and inflammatory proteins refers to a biomimetic therapeutic strategy rather than a single molecular target. This approach leverages the natural homing capabilities of neutrophils, which utilize surface receptors like L-selectin (CD62L) and Mac-1 (CD11b/CD18) to navigate toward inflammatory sites (Kolaczkowska & Kubes, 2013, Nature Reviews Immunology). By coating synthetic nanoparticles with purified neutrophil membranes, researchers create "decoys" that present a wide array of receptors, such as CXCR1 and CXCR2, capable of binding and neutralizing pro-inflammatory cytokines like TNF-alpha and IL-1 beta (Zhang et al., 2017, Nature Nanotechnology). This system is designed to mitigate the "cytokine storm" in conditions like sepsis and acute respiratory distress syndrome (ARDS) while minimizing the systemic side effects of broad immunosuppressants. Additionally, these membrane-coated platforms can be loaded with drugs to provide targeted delivery to inflamed tissues or tumors, exploiting the neutrophil's innate chemotactic response to inflammatory proteins (Wang et al., 2020, Advanced Materials). While highly promising for precision medicine, significant challenges remain regarding the standardization of membrane extraction and the potential immunogenicity of the cellular components.

Other names

Neutrophil-mimetic nanoparticlesNeutrophil membrane-coated vesiclesNeutrophil decoysNeutrophil-based biomimetic platforms

Decoy-based neutralization of pro-inflammatory cytokines and targeted delivery via chemotactic homing to inflamed tissues.